scholarly journals Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database

Liver Cancer ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. 156-166
Author(s):  
Junichi Shindoh ◽  
Yuta Kobayashi ◽  
Yusuke Kawamura ◽  
Norio Akuta ◽  
Masahiro Kobayashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Oncological Outcome ◽  
Staging System ◽  
Cancer Staging ◽  
Microvascular Invasion ◽  
Cutoff Value ◽  
American Joint Committee ◽  
Multiple Hepatocellular Carcinoma ◽  
End Results

scholarly journals Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System for Solitary Tumors

2012 ◽  
Vol 20 (4) ◽  
pp. 1223-1229 ◽  
Author(s):  
Junichi Shindoh ◽  
Andreas Andreou ◽  
Thomas A. Aloia ◽  
Giuseppe Zimmitti ◽  
Gregory Y. Lauwers ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Staging System ◽  
Microvascular Invasion ◽  
Term Survival ◽  
Long Term Survival

Surgical Treatment for Hepatocellular Carcinoma in the Era of Multiple Staging and Algorithm

2018 ◽  
Author(s):  
Suguru Yamashita ◽  
Katharina Joechle ◽  
Jean-Nicolas Vauthey
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Treatment Algorithm ◽  
Staging System ◽  
Cancer Staging ◽  
Barcelona Clinic Liver Cancer ◽  
Term Survival ◽  
American Joint Committee ◽  
Staging Systems ◽  
Surgical Treatments

A plethora of staging systems for hepatocellular carcinoma (HCC) has existed, as the management for HCC is made complex by the interplay of tumor characteristics and the health and underlying functions of both the patient and the liver. The majority of patients with HCC have nonsurgical HCC. The Barcelona Clinic Liver Cancer (BCLC) classification has been regarded as the optimal staging system and treatment algorithm for HCC. However, even in patients with intermediate or advanced stage in BCLC classification, who had not been originally recommended to undergo surgery, some could benefit in terms of long-term survival by surgical treatments. An expert panel on HCC has stated that the American Joint Committee on Cancer staging system, whose predictive power on the outcome have been improved by continuous amendments, should be applied for patients undergoing surgery. Herein, we review the recent staging system focusing on patients with HCC undergoing surgery.   This review contains 5 figures, 3 tables and 34 references Key Words: American Joint Committee on Cancer, Barcelona Clinic Liver Cancer, hepatic resection, hepatocellular carcinoma, orthotopic liver transplantation

Surgical Treatment for Hepatocellular Carcinoma in the Era of Multiple Staging and Algorithm

2018 ◽  
Author(s):  
Suguru Yamashita ◽  
Katharina Joechle ◽  
Jean-Nicolas Vauthey
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Treatment Algorithm ◽  
Staging System ◽  
Cancer Staging ◽  
Barcelona Clinic Liver Cancer ◽  
Term Survival ◽  
American Joint Committee ◽  
Staging Systems ◽  
Surgical Treatments

A plethora of staging systems for hepatocellular carcinoma (HCC) has existed, as the management for HCC is made complex by the interplay of tumor characteristics and the health and underlying functions of both the patient and the liver. The majority of patients with HCC have nonsurgical HCC. The Barcelona Clinic Liver Cancer (BCLC) classification has been regarded as the optimal staging system and treatment algorithm for HCC. However, even in patients with intermediate or advanced stage in BCLC classification, who had not been originally recommended to undergo surgery, some could benefit in terms of long-term survival by surgical treatments. An expert panel on HCC has stated that the American Joint Committee on Cancer staging system, whose predictive power on the outcome have been improved by continuous amendments, should be applied for patients undergoing surgery. Herein, we review the recent staging system focusing on patients with HCC undergoing surgery.   This review contains 5 figures, 3 tables and 34 references Key Words: American Joint Committee on Cancer, Barcelona Clinic Liver Cancer, hepatic resection, hepatocellular carcinoma, orthotopic liver transplantation

scholarly journals Tumor size may influence the prognosis of solitary hepatocellular carcinoma patients with cirrhosis and without macrovascular invasion after hepatectomy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Bin-yong Liang ◽  
Jin Gu ◽  
Min Xiong ◽  
Er-lei Zhang ◽  
Zun-yi Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Tumor Size ◽  
Staging System ◽  
Prognostic Impact ◽  
Term Survival ◽  
Long Term Survival ◽  
Before And After ◽  
Cirrhotic Patients ◽  
Curative Hepatectomy

AbstractHepatocellular carcinoma (HCC) is usually associated with varying degrees of cirrhosis. Among cirrhotic patients with solitary HCC in the absence of macro-vascular invasion, whether tumor size drives prognosis or not after hepatectomy remains unknown. This study aimed to investigate the prognostic impact of tumor size on long-term outcomes after hepatectomy for solitary HCC patients with cirrhosis and without macrovascular invasion. A total of 813 cirrhotic patients who underwent curative hepatectomy for solitary HCC and without macrovascular invasion between 2001 and 2014 were retrospectively studied. We set 5 cm as the tumor cut-off value. Propensity score matching (PSM) was performed to minimize the influence of potential confounders including cirrhotic severity that was histologically assessed according to the Laennec staging system. Recurrence-free survival (RFS) and overall survival (OS) were compared between the two groups before and after PSM. Overall, 464 patients had tumor size ≤ 5 cm, and 349 had tumor size > 5 cm. The 5-year RFS and OS rates were 38.3% and 61.5% in the  ≤ 5 cm group, compared with 25.1% and 59.9% in the > 5 cm group. Long-term survival outcomes were significantly worse as tumor size increased. Multivariate analysis indicated that tumor size > 5 cm was an independent risk factor for tumor recurrence and long-term survival. These results were further confirmed in the PSM cohort of 235 pairs of patients. In cirrhotic patients with solitary HCC and without macrovascular invasion, tumor size may significantly affect the prognosis after curative hepatectomy.

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 ◽  
Vol 19 (16) ◽  
pp. 3635-3648 ◽  
Author(s):  
Charles M. Balch ◽  
Antonio C. Buzaid ◽  
Seng-Jaw Soong ◽  
Michael B. Atkins ◽  
Natale Cascinelli ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Elevated Serum ◽  
Primary Melanoma ◽  
Staging System ◽  
Distant Metastases ◽  
Lactic Dehydrogenase ◽  
Cancer Staging ◽  
Sixth Edition ◽  
Stage Grouping ◽  
American Joint Committee

PURPOSE: To revise the staging system for cutaneous melanoma under the auspices of the American Joint Committee on Cancer (AJCC). MATERIALS AND METHODS: The prognostic factors analysis described in the companion publication (this issue), as well as evidence from the published literature, was used to assemble the tumor-node-metastasis criteria and stage grouping for the melanoma staging system. RESULTS: Major changes include (1) melanoma thickness and ulceration but not level of invasion to be used in the T category (except for T1 melanomas); (2) the number of metastatic lymph nodes rather than their gross dimensions and the delineation of clinically occult (ie, microscopic) versus clinically apparent (ie, macroscopic) nodal metastases to be used in the N category; (3) the site of distant metastases and the presence of elevated serum lactic dehydrogenase to be used in the M category; (4) an upstaging of all patients with stage I, II, and III disease when a primary melanoma is ulcerated; (5) a merging of satellite metastases around a primary melanoma and in-transit metastases into a single staging entity that is grouped into stage III disease; and (6) a new convention for defining clinical and pathologic staging so as to take into account the staging information gained from intraoperative lymphatic mapping and sentinel node biopsy. CONCLUSION: This revision will become official with publication of the sixth edition of the AJCC Cancer Staging Manual in the year 2002.

Sign in / Sign up

Export Citation Format

Share Document